Screener
Apogee Therapeutics, Inc. APGE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Net loss | $(74,111) | $(55,339) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation expense | 408 | 207 |
| Equity-based compensation expense | 17,155 | 11,126 |
| Amortization of discounts on marketable securities | (1,549) | (2,379) |
| Non-cash lease expense | 980 | 857 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,490) | 895 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s stock-based comp?
- Apogee Therapeutics, Inc. (APGE) reported stock-based comp of $17.16M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Apogee Therapeutics, Inc.'s stock-based comp increased by 54.2% year-over-year, from $11.13M to $17.16M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s stock-based comp?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s stock-based comp has grown at a 175.4% compound annual growth rate (CAGR), from $6.1M to $46.28M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Apogee Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude